Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.922,16
    +40,66 (+0,12%)
     

  • Dow Jones

    37.916,74
    +141,36 (+0,37%)
     

  • Nasdaq

    15.272,66
    -328,84 (-2,11%)
     

  • Nikkei 225

    37.068,35
    -1.011,35 (-2,66%)
     

  • Petrolio

    83,46
    +0,73 (+0,88%)
     

  • Bitcoin EUR

    60.273,11
    +847,56 (+1,43%)
     

  • CMC Crypto 200

    1.379,96
    +67,34 (+5,13%)
     

  • Oro

    2.411,30
    +13,30 (+0,55%)
     

  • EUR/USD

    1,0653
    +0,0007 (+0,06%)
     

  • S&P 500

    4.963,98
    -47,14 (-0,94%)
     

  • HANG SENG

    16.224,14
    -161,73 (-0,99%)
     

  • Euro Stoxx 50

    4.918,09
    -18,48 (-0,37%)
     

  • EUR/GBP

    0,8610
    +0,0054 (+0,63%)
     

  • EUR/CHF

    0,9693
    -0,0018 (-0,18%)
     

  • EUR/CAD

    1,4645
    -0,0005 (-0,04%)
     

Novan to Report Third Quarter 2022 Financial Results on November 14, 2022

Novan, Inc.
·2 minuto per la lettura
Novan, Inc.
Novan, Inc.

DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday, November 14th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.

About Novan

Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with current emphasis on molluscum contagiosum.

ANNUNCIO PUBBLICITARIO

Novan recently completed the acquisition of EPI Health. EPI Health equips the company with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, the company employs approximately 100 staff, including sales personnel currently covering 42 territories, and promotes products for plaque psoriasis, rosacea, acne and dermatoses. Novan also has a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com